Charles River Laboratories | CRL - Ebitda


Charles River Laboratories reported $272.95M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Agilent USD 456M 84M Dec/2025
Align Technology USD 229.14M 31.74M Mar/2026
Bio-Rad Laboratories USD -636.6M 1.62B Mar/2026
Bruker USD 143.2M 33.2M Jun/2026
Cardinal Health USD 1.09B 109M Mar/2026
Charles River Laboratories USD 272.95M 43.14M Jun/2026
Cigna USD 3.28B 416M Mar/2026
CVS Health USD 5.85B 25M Jun/2026
Danaher USD 1.84B 81M Jun/2026
Dentsply International USD 129M 6M Mar/2026
Elevance Health USD 4.21B 2.02B Mar/2026
Humana USD 2.06B 2.35B Mar/2026
Illumina USD 330M 80M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
IQVIA Holdings USD 994M 62M Jun/2026
Laboratory Of America USD 767.7M 162.1M Jun/2026
Lakefront Biotherapeutics EUR -63.7M 624.2M Mar/2026
Lonza CHF 1.01B 54M Dec/2025
McKesson USD 1.71B 674M Jun/2026
Merck EUR 1.53B 87M Mar/2026
Mettler Toledo International USD 322.64M 43.66M Jun/2026
Novartis USD 6.48B 1.19B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Quest Diagnostics USD 648M 91M Jun/2026
Revvity USD 228.18M 44.73M Jun/2026
Thermo Fisher Scientific USD 3.55B 845M Jun/2026
United Therapeutics USD 355M 11.1M Jun/2026
UnitedHealth USD 9.43B 567M Jun/2026
Veradigm USD 38.81M 29.61M Sep/2022
Waters USD 712M 545M Jun/2026
West Pharmaceutical Services USD 243.6M 17.4M Jun/2026